申请人:Astellas Pharma, Inc.
公开号:US07919495B2
公开(公告)日:2011-04-05
To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.
We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.
为了治疗与脂肪酸酰胺水解酶(FAAH)相关的疾病,特别是治疗尿频和尿失禁、过度活动的膀胱和/或疼痛,提供一种化合物。我们发现一种新型的吡啶基非芳香性含氮杂环-1-羧酸酯衍生物及其药学上可接受的盐具有强效的FAAH抑制活性。此外,本发明的吡啶基非芳香性含氮杂环-1-羧酸酯衍生物对增加有效膀胱容量、缓解尿频和具有出色的抗痛觉过敏效果,因此可用于治疗尿频和尿失禁、过度活动的膀胱和/或疼痛。